MAI CDMO Network | Search and find the CMO / CDMO you need

Small

Medium

Large

Investigational

Commercial (Phase IV)

Human

Veterinary

1 / low-hazard (PDE > 10,000 µg/day)

2 (PDE = 1,000 - 10,000 µg/day)

3 (PDE = 100 - 1,000 µg/day)

4 / HPAPI (PDE = 10 - 100 µg/day)

5 / HPAPI (PDE < 10 µg/day)

Lowest potential for abuse

Low potential for abuse

Lower potential for abuse

High potential for abuse & medical use

High potential for abuse & no medical use

Zastosowane filtry:BFS (Blow Fill Seal) ampolues×Wyczyść wszystko

Seans 7 udogodnienia

Sortuj według:

Norwegia

Adragos Pharma | Halden

Adragos Pharma

Specjalizujemy się w produkcji worków infuzyjnych, ampułek plastikowych i fiolek z wykorzystaniem technologii Blow-Fill-Seal (BFS) oraz innych form dawkowania.

Odkryj nasz obiekt

RYNKI: Turkish Health Authorities, EDE (UAE), ANVISA (Brazil), PMDA (Japan), FDA (USA), EMA (EU), MFDS (South Korea), SFDA (Saudi Arabia), TGA (Australia), NMPA (China), MHRA (UK)

ROZMIAR PARTII: Small, Medium, Large

KATEGORIA / PRODUKT: FDF / PRODUKTY LEKOWE

ZGODNOŚĆ: EMA (EU GMP), PMDA/MHLW (Japan GMP), UAE Ministry of Health & Prevention, ANVISA (Brazil B-GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), TGA (Australia GMP), FDA (cGMP), NSF, NMPA (China GMP), ISO, TITCK (Turkish Health Authorities), MFDS/KFDA (Republic of Korea GMP)

SUBSTANCJE KONTROLOWANE: Lowest potential for abuse, High potential for abuse & medical use, Lower potential for abuse, Low potential for abuse

REGION: Europa

UŻYWAĆ: Human

USŁUGI: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Packaging, Quality Assurance services

OEB (pasmo narażenia zawodowego): 2 (PDE = 1,000 - 10,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day)

TERAPEUTYCZNE OBSZARY WIEDZY (ATC): (A) Digestive tract and metabolism, (D) Dermatologicals, (V06) Nutrients